We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of a Probiotic Food Supplement Containing B. Infantis (EVC001) in Healthy Breastfed Infants at Risk of Developing Atopic Dermatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04662619
Recruitment Status : Active, not recruiting
First Posted : December 10, 2020
Last Update Posted : March 22, 2023
Sponsor:
Collaborators:
Evolve BioSystems, Inc.
Janssen World Without Disease Accelerator (WWDA) Healthy Baby Initiative (HBI)
Information provided by (Responsible Party):
Johnson & Johnson Consumer and Personal Products Worldwide ( Johnson & Johnson Consumer Inc. (J&JCI) )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to assess the effect of B. infantis (EVC001) versus placebo supplementation, in healthy breastfed infants at risk of developing atopic dermatitis (AD), on cumulative incidence of physician-diagnosed AD during the first year of life.

Condition or disease Intervention/treatment Phase
Healthy Other: B. infantis Other: Lactose Placebo Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 273 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Parallel-Group, Nutritional Intervention Study to Examine the Clinical and Immunological Effects of a Probiotic Food Supplement Containing B. Infantis (EVC001) in Healthy Breastfed Infants at Risk of Developing Atopic Dermatitis
Actual Study Start Date : December 18, 2020
Estimated Primary Completion Date : November 20, 2023
Estimated Study Completion Date : November 18, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breastfeeding Eczema

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: B. infantis
A once-daily feeding of activated B. infantis EVC001 (8.0 *10^9 colony forming units [CFU]) will be provided to infants for 12 weeks.
 Other: B. infantis
Bifidobacterium longum subspecies infantis strain EVC001, designated a "Foods for Special Dietary Use" (FSDU), will be provided to infants once daily for 12 weeks.
Other Name: Evivo
Placebo Comparator: Placebo
A once-daily oral feeding of lactose placebo will be provided to infants for 12 weeks.
 Other: Lactose Placebo
Powdered infant formula grade lactose will be provided to infants once daily for 12 weeks.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of Participants with Atopic Dermatitis (AD) through Week 52 [ Time Frame: Up to Week 52 ]
    Number of participants with atopic dermatitis (AD) through Week 52 will be reported. AD will be diagnosed if three of the following four criteria are met: 1) pruritus, 2) typical morphology and distribution (facial and extensor involvement), 3) chronic or chronically relapsing dermatitis, 4) personal or family history of atopic disease.


Secondary Outcome Measures :
  1. Percentage of Infants with Adverse Events Through Weeks 12, 52 and 104 [ Time Frame: Up to Weeks 12, 52 and 104 ]
    The percentage of infants with AEs, serious adverse events (SAEs), AEs leading to discontinuation, and AEs related to the gastrointestinal system will be determined at Weeks 12, 52 and 104.

  2. Number of Participants with Atopic Dermatitis (AD) Through Weeks 24 and 104 [ Time Frame: Up to Weeks 24 and 104 ]
    Number of participants with AD through Week 24 and 104 will be reported. AD will be diagnosed if three of the following four criteria are met: 1) pruritus, 2) typical morphology and distribution (facial and extensor involvement), 3) chronic or chronically relapsing dermatitis, 4) personal or family history of atopic disease.

  3. Time to Onset of AD Through Weeks 52 and 104 [ Time Frame: Up to Weeks 52 and 104 ]
    Time to onset of AD through Weeks 52 and 104 will be reported.

  4. Percentage of Infants with B. infantis Gut Colonization at Week 12 [ Time Frame: Week 12 ]
    Percentage of infants with B. infantis gut colonization at Week 12 will be reported.

  5. Atopic Dermatitis (AD) Severity Based on the Eczema Area and Severity Index (EASI) Score at Time of AD Onset and at Weeks 12, 52, and 104 [ Time Frame: At the time of AD onset (up to Week 104), Weeks 12, 52, and 104 ]
    Atopic Dermatitis (AD) severity based on the EASI score at time of AD onset and at Weeks 12, 52, and 104 will be reported. Physician rates severity of four parameters: erythema, infiltration, excoriation and lichenification on a scale of 0 (none) to 3 (severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Physician determines how much area is affected on a scale of 0 (none) to 6 (90 to 100%). A body region score is determined by multiplying the sum of the severity scores by the affected area score by a constant corresponding to the relative body surface area for that body region (20%, 30%, 20%, and 30%, respectively). The 4 body region scores are summed to yield the EASI score which ranges from 0 to 72, with a higher score indicating more severe AD. The AD onset in the study's population can be diagnosed throughout the study at either scheduled or unscheduled visits starting as early as 1 month of age.

  6. AD Severity Based on the Patient-Oriented Eczema Measure (POEM) Score at Time of AD Onset and at Weeks 12, 52, and 104 [ Time Frame: At the time of AD onset (up to Week 104), Weeks 12, 52, and 104 ]
    The POEM is a simple, valid, easily interpreted, and reproducible tool for assessing AD and monitoring aspects of the disease that are important to participants with AD. Study Personnel will interview Caregivers at time of AD diagnosis and (only for participants with AD) at Weeks 12, 52, and 104 to rate seven symptoms (itchy skin, sleep disturbance, bleeding skin, skin weeping/oozing, skin flaking, skin cracking, skin dryness/roughness) using a 5-point scale of frequency of occurrence during the previous week (no days, 1-2 days, 3-4 days, 5-6 days, every day). The total score is the sum of the 7 items which is ranged from 0 to 28; a high score is indicative of more severe AD. The AD onset in the study's population can be diagnosed throughout the study at either scheduled or unscheduled visits starting as early as 1 month of age.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 14 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy term infant
  • Has at least one first degree relative (that is biological parent or full sibling) with a history of atopic disease (that is mother-reported, physician-diagnosed Atopic Dermatitis (AD), allergic rhinitis, or asthma)
  • Breastfeeding established (as determined by the principal Investigator [PI] or designee) at the time of study enrollment (Day 0), with maternal intent to maintain exclusive breastfeeding for greater than or equal to (>=)12 weeks
  • Will participate in the study under supervision of his/her biological mother ("Caregiver") who is: a) At least 18 years old b) The legal guardian of the infant c) Intending to cohabitate with the infant for the duration of the study d) Willing to follow all Caregiver responsibilities e) Fluent in Finnish, Swedish, or English
  • The PI considers the Caregiver likely to adequately comply with the study protocol requirements based on demonstrated compliance with antenatal appointments and agreement to complete the intuitive, interactive, electronic diary (eDiary) utilizing personal smart device (example, tablet, cell phone)

Exclusion Criteria:

  • Preterm delivery (< 36 weeks [252 days] gestational age)
  • Admission to the neonatal unit for issues other than establishment of normal feeding
  • Evidence of a baseline illness/condition (example abnormal birth weight) or significant risk of developing an illness/condition (based on review of maternal/pregnancy information) that would, in the opinion of the Principal Investigator (PI) or designee, introduce a significant safety concern if the infant were enrolled in the study or otherwise preclude study participation
  • Significant birth defect/complication that would, in the opinion of the PI or designee, create a safety concern or otherwise confound the study (example, abdominal wall defects, congenital heart disease)
  • Severe widespread skin condition (example collodion)
  • Has consumed greater than (>)100 milliliter (mL) of formula per day within the 48 hours prior to enrollment (Day 0)
  • Twin or multiple births
  • Atopic dermatitis (AD) diagnosed at Day 0
  • Has a history of confirmed coronavirus disease 2019 (COVID-19) within 30 days prior to any on-site visit
  • Within 14 days prior to Visit 1, has been in close contact (exposure within 6 feet for a cumulative time of 15 minutes or more over a 24-hour period) with anyone who has a confirmed case of COVID-19
  • Is under a COVID-19 isolation/quarantine order
  • Has had self-reported (for Caregiver) or parent-reported (for infant) symptoms of COVID-19 within 14 days prior to the screening visit, such as unexplained cough, shortness of breath/difficulty breathing, fatigue, body aches (headaches, muscle pain, stomachaches), conjunctivitis, loss of smell, loss of taste, poor appetite, nausea, vomiting, diarrhea, palpitations, or chest pain/tightness
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04662619


Locations
Layout table for location information
Finland
HUS Children and Adolescents, Clinical Trial Unit, Park Hospital
Helsinki, Finland, 00290
Sponsors and Collaborators
Johnson & Johnson Consumer Inc. (J&JCI)
Evolve BioSystems, Inc.
Janssen World Without Disease Accelerator (WWDA) Healthy Baby Initiative (HBI)
Investigators
Layout table for investigator information
Principal Investigator: Samuli Rautava, M.D., Ph.D. Helsinki University Central Hospital
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Other Publications:
Kela.fi: Maternity, Paternity and Parental Allowances [Internet]. Helsinki (Finland): Kansaneläkelaitos - The Social Insurance Institution of Finland; [updated 2020 Jan 16; cited 2020 Apr 27]. Available from: https://www.kela.fi/web/en/parental-allowances.
Stm.fi: Maternity and Child Health Clinics [Internet]. Helsinki (Finland): Ministry of Social Affairs and Health; [cited 2020 Apr 27]. Available from: https://stm.fi/en/maternity-and-child-health-clinics.

Layout table for additonal information
Responsible Party: Johnson & Johnson Consumer Inc. (J&JCI)
ClinicalTrials.gov Identifier: NCT04662619    
Other Study ID Numbers: CCSNUT002443
CCSNUT002443 ( Other Identifier: Johnson & Johnson Consumer Inc. )
First Posted: December 10, 2020    Key Record Dates
Last Update Posted: March 22, 2023
Last Verified: March 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Johnson & Johnson Consumer Inc. has an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.
URL: http://yoda.yale.edu

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
 Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases